Sign inJoin free

Watch / Small Cap

Big picture for small caps | Neuren drug fast tracked by FDA

22 June 202217:43

Big picture for small caps | Neuren drug fast tracked by FDA

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Even as interest rates rise there are still some economies that are going strong and Niv Dagen from Peak Asset Management explains all. He says Canadian retail sales came in at 0.9% which was better than expected showing consumers are still wanting to spend, but on the other side of the pond in New Zealand consumer confidence was taking a hit. The small cap outlook looks solid, he says most of the market has already factored in interest rate rises, but the question for investors is how much has been factored? Lithium has strong buying opportunities and Niv speaks about Lake Resources (LKE) and Askari Metals (AS2). And he likes those low cost and high market gold producers like Newcrest (NCM) | Neuren Pharmaceuticals (NEU) is turning down the final straight to get its lead compound, Trofinetide approved by the US Food and Drug Administration. The drug is in phase three trials and targets the treatment of Rett syndrome - a rare neurological condition which affects the development of the brain. CEO, Jon Pilcher says its been a long road to get to this point and the management team is highly motivated to get Trofinetide across the line for shareholders' sake, but primarily for the children and families affected by Retts. Jon says Neuren is working with Acadia Pharmaceuticals for the development and commercialisation in North America. Tune into the full chat to get across Neuren's next project, which Jon says is "even more promising" than the last!

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy